This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data."

Transcription

1 abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical study report had been prepared in accordance with best practice and applicable legal and regulatory requirements at the time of study completion. The synopsis may include approved and non approved uses, doses, formulations, treatment regimens and/or age groups; it has not necessarily been submitted to regulatory authorities. A synopsis is not intended to provide a comprehensive analysis of all data currently available regarding a particular drug. More current information regarding a drug is available in the approved labeling information which may vary from country to country.. Additional information on this study and the drug concerned may be provided upon request based on s Policy on Transparency and Publication of Clinical Study Data. The synopsis is supplied for informational purposes only in the interests of scientific disclosure. It must not be used for any commercial purposes and must not be distributed, published, modified, reused, posted in any way, or used for any other purpose without the express written permission of.

2 1 of NOV / 23 NOV JUN 2008 Title of trial: Telmisartan Randomized AssessmeNt Study in ace intolerant subjects with cardiovascular Disease (TRANSCEND) Coordinating Investigator: A large, simple, randomized, double-blind, multicentre, international trial comparing the effects of telmisartan with placebo on outcomes in patients at high risk for cardiovascular events and intolerant of ACE-I Trial sites: Multicentre study, cf. Appendix Publication (reference): Clinical phase: Objectives: Methodology: TRANSCEND Investigators. Lancet 2008;372: [P ] Department of error. Erratum for: 'TRANSCEND Investigators. Lancet 2008;372: '. Lancet 2008;372(9647): 1384 [P ] Sleight P. Acta Diabetol 2005;42:S50-S56 [P ] ONTARGET/TRANSCEND Investigators. Am Heart J 2004;148(1):52-61 [P ] III The objective of the TRANSCEND trial was to determine if telmisartan 80 mg daily is superior to placebo in reducing the composite endpoint of cardiovascular (CV) death, myocardial infarction (MI), stroke and hospitalisation for congestive heart failure (CHF) in patients who are intolerant to angiotensin converting enzyme-inhibitors (ACE-Is). Randomised (1:1 ratio), double-blind, parallel-group, placebo-controlled trial with a single-blind run-in phase of 3 to 4 weeks (starting with placebo for 1 week, continuing with telmisartan 80 mg for 2 to 3 weeks), and a planned randomised treatment phase of 3.5 to 6 years; patients were randomised to either monotherapy with telmisartan (80 mg) or to placebo. All patients in this trial received concomitant medication according to their medical needs.

3 2 of 12 No. of subjects: planned: entered: at least 5000 patients as per original trial protocol at least 6000 patients as per Amendment 2.1 (dated 17 April 2003) actual: Diagnosis and main criteria for inclusion: enrolled (run-in period): 6665 patients entered (randomised period): 5926 patients Telmisartan: entered: 2954 patients; analysed (for primary endpoint): 2954 patients Placebo: entered: 2972 patients; analysed (for primary endpoint): 2972 patients Male or female patients, 55 years of age or older, and at a high risk of CV events indicated by: 1. Coronary artery disease (CAD) defined as: a) Previous MI (>2 days post uncomplicated MI, prior to informed consent), or b) Stable or unstable angina (>30 days prior to informed consent) each with documented multi-vessel coronary disease, >50% stenosis in at least 2 major coronary arteries on coronary angiography, or positive stress test (ST depression 2 mm or a positive nuclear perfusion scintigram), or c) Multi-vessel percutaneous transluminal coronary angioplasty (PTCA) >30 days prior to informed consent, or d) Multi-vessel coronary artery bypass graft (CABG) surgery without angina (>4 years prior to informed consent), or with recurrent angina following surgery. 2. Peripheral arterial disease (PAD) defined as: a) Previous limb bypass surgery or percutaneous transluminal angioplasty, or b) Previous limb or foot amputation, or c) History of intermittent claudication, with an ankle/arm blood pressure (BP) ratio of 0.80 on at least one side, or d) Significant peripheral artery stenosis (>50%) documented by angiography on non-invasive testing. 3. Previous stroke (including definite or presumed cerebral infarction, intracerebral haemorrhage, stroke of uncertain subtype, but not subarachnoid haemorrhage).

4 3 of Transient ischaemic attack (TIA) >7 days and <1 year prior to informed consent (TIA defined as acute loss of focal cerebral or monocular function with symptoms lasting <24 hours, and thought to be due to inadequate cerebral or ocular blood supply as a result of arterial thrombosis or embolism). Test product: 5. High-risk diabetes (insulin-dependent or non-insulin-dependent) with evidence of end-organ damage (retinopathy, left ventricular hypertrophy, or any evidence of previous cardiac or vascular disease). Only patients with known intolerance to ACE-Is according to their medical history or as assessed during the run-in period of the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) were included into this trial. Telmisartan dose: Run-in period: 1 week telmisartan-matching placebo, followed by 2 to 3 weeks telmisartan 80 mg Randomised period: telmisartan 80 mg daily mode of admin.: Oral batch no.: Refer to Appendix Reference therapy: Telmisartan-matching placebo dose: Run-in period: 1 week telmisartan-matching placebo, followed by 2 to 3 weeks telmisartan 80 mg Randomised period: placebo matching telmisartan 80 mg mode of admin.: Oral batch no.: Refer to Appendix Duration of treatment: Run-in period: 1 week telmisartan-matching placebo, followed by 2 to 3 weeks telmisartan 80 mg Randomised period: planned: minimum of 3.5 years, maximum of 6 years actual median observation time: telmisartan: 1766 days placebo: 1772 days

5 4 of 12 Criteria for evaluation: Efficacy / clinical pharmacology: Primary endpoint: Composite of CV death, MI, stroke, or hospitalisation for CHF Secondary endpoints: - Composite of CV death, non-fatal MI, and non-fatal stroke - The individual components of the primary endpoint - Occurrence of nephropathy analysed based on the following 6 subcategories: Doubling of serum creatinine Progression to end-stage renal disease [ESRD] (i.e. initiation of dialysis, need for renal transplantation, or estimated glomerular filtration rate [egfr] <15 ml/min/1.73m 2 ) New microalbuminuria (urinary albumine creatinine ratio [UACR] 30 mg/g creatinine [Crea] in patients with a UACR <30 mg/g Crea at baseline) New macroalbuminuria (UACR 300 mg/g Crea in patients with a UACR <300 mg/g Crea at baseline) Combined endpoint of doubling of serum creatinine, progression to ESRD, new microalbuminuria, or new macroalbuminuria Normalisation from micro- or macroalbuminuria to normoalbuminuria (UACR <30 mg/g Crea in patients with a UACR 30 mg/g Crea at baseline) - Newly diagnosed CHF - CV revascularisation procedures - Newly diagnosed diabetes - Cognitive impairment and cognitive decline - New onset of atrial fibrillation Other endpoints: - All-cause mortality (= non-cv mortality + CV mortality) Non-CV death - Angina (unstable, new, and worsening) - TIA - Malignancy (fatal and non-fatal) - Laser therapy for diabetic retinopathy

6 5 of 12 Additionally, changes from baseline in BP, ankle/arm BP ratio, Mini Mental State Examination (MMSE), egfr, serum creatinine, and UACR were determined. Safety: Statistical methods: Serious adverse events (SAEs, coded using the Medical Dictionary for Regulatory Activities [MedDRA]), adverse events (AEs) leading to discontinuation of trial medication (coded using an internal coding system); clinical laboratory evaluations; vital signs (BP and pulse rate), electrocardiograms [ECGs]. Primary and secondary outcome events: time-to-event analysis (Kaplan Meier) and hazard ratios based on the intent-to-treat principle and using the proportional hazard model (Cox regression); χ 2 -test for cognitive impairment and cognitive decline Sensitivity analyses: Cox regression including covariates, χ 2 -test Descriptive statistics, analysis of covariance (ANCOVA) SUMMARY CONCLUSIONS: Efficacy / clinical pharmacology results: A total of 6665 patients were enrolled by 650 centres worldwide. After a singleblind run-in period of 3 to 4 weeks, a total of 5926 patients were randomised to either telmisartan 80 mg (2954 patients) or placebo (2972 patients). All patients received concomitant medication according to their medical needs. The most frequent reasons for non-randomisation were the patients' request to stop treatment (6.1%), insufficient compliance with study medication (5.1%), and the occurrence of AEs (2.6%). The majority of patients (99.7% of randomised patients) completed the trial with identical proportions in the 2 treatment groups; 'completed' was defined as final visit performed or vital status confirmed (including death) at the end of the trial. A total of 18.5% of all randomised patients permanently discontinued study medication (telmisartan: 17.7%; placebo: 19.4%) with a trend for fewer discontinuations in the telmisartan group (risk ratio for telmisartan vs. placebo: 0.91; 95% CI 0.82, 1.02; p=0.0969). Of those who permanently discontinued study medication, 42.9% stopped due to AEs (telmisartan: 47.2%; placebo: 39.1%). Demographics and baseline characteristics of the randomised patients were similar in the 2 treatment groups. The mean age of patients was 66.9 years;

7 6 of % of patients were male. Most patients were of white ethnicity (62.4%); 21.3% of patients were Asian, and 1.8% were black. For the majority of patients, CAD was the primary risk factor for inclusion in the trial (66.8%). At baseline, hypertension was present in 86.0% of patients and diabetes mellitus in 41.6%. The majority of patients received acetylsalicylic acid (74.7% at baseline, 71.2% at study end), beta blockers (58.3% at baseline, 57.8% at study end), and statins (55.2% at baseline, increasing to 63.5% at study end). After randomisation, differences between treatment groups in the use of concomitant medication were seen for diuretics (33.0% at baseline, 33.7% at study end in the telmisartan group, 40.0% at study end in the placebo group), calcium channel blockers excluding diltiazem/verapamil (31.1% at baseline, 30.8% vs. 39.2%, respectively, at study end), and beta blockers (58.3% at baseline, 56.6% vs. 59.0%, respectively, at study end). The mean systolic/diastolic blood pressure (SBP/DBP) at baseline was 141.0/81.9 mmhg and did not differ between treatment groups. During the runin period, patients received telmisartan-matching placebo for 1 week, followed by telmisartan 80 mg for 2 to 3 weeks. When patients were randomised following the run-in period, the mean SPB/DPB had decreased similarly in both treatment groups (telmisartan: 5.9/ 4.0 mmhg, placebo: 6.1/ 4.0 mmhg). At the 6 week visit, the BP in the telmisartan group had further decreased (mean change from baseline: 7.2/ 4.8 mmhg) while it had almost returned to baseline levels in the placebo group (mean change from baseline: 1.0/ 1.2 mmhg). These treatment differences in BP were generally maintained throughout the study. The weighted mean change from baseline post-randomisation was 6.5/ 4.9 mmhg with telmisartan and 2.3/ 2.6 mmhg with placebo. At baseline, no differences between treatment groups were observed for the mean egfr, mean serum creatinine, or geometric mean UACR. Patient compliance with study medication during the randomised period was high at all visits. At the final visit, 79.2% of patients in the telmisartan group and 77.1% in the placebo group were compliant with study medication. Primary endpoint The primary composite endpoint occurred in 465 patients (15.7%) in the telmisartan group and 504 patients (17.0%) in the placebo group; the event rates per 100 patient years were 3.58 and 3.87, respectively. The hazard ratio (HR) of telmisartan vs. placebo was 0.92 (95% CI 0.81, 1.05; p = ). The trial could not demonstrate superiority of telmisartan over placebo in the prevention of CV

8 7 of 12 death, non-fatal MI, non-fatal stroke, and hospitalisation for CHF. For non-fatal stroke and non-fatal MI, incidences were lower in the telmisartan group than in the placebo group (non-fatal MI: 3.6% vs. 4.6%, non-fatal stroke: 3.6% vs. 4.3%); no relevant differences were seen for hospitalisation for CHF and CV death. Baseline SBP and SBP changes over time did not substantially influence the results for the primary endpoint; the SBP-adjusted hazard ratio of telmisartan vs. placebo was 0.94 (95% CI 0.83, 1.07). The TRANSCEND trial had been planned based on the event rates observed in the previous Heart Outcomes Prevention Evaluation (HOPE) trial. Under these assumptions, a sample size of 3000 patients per treatment group to be recruited within 2 years and to be observed for a maximum of 5.5 years would have had a power of approximately 94% to establish the superiority of telmisartan over placebo. However, the observed yearly event rates in TRANSCEND were lower than expected. This was mainly due to the improved standard of medical care at the time the TRANSCEND trial was performed, which was reflected e.g. in the more frequent use of concomitant medications and of revascularisation procedures in patients in TRANSCEND. According to a retrospective power calculation with the number of patients randomised and the actual recruitment and observation periods and assuming that the observed event rates are real, the TRANSCEND study had a limited statistical power and as such only a 25% chance of demonstrating superiority of telmisartan over placebo. The Kaplan-Meier analysis suggested that the assumption of proportional hazards was not fulfilled for the primary composite endpoint as well as for the secondary composite endpoint of CV death, MI, and stroke. Hence, this was investigated using a Cox proportional hazards model with the categorised time to first event ( 6 months, >6 months) as covariate. No treatment difference was seen for the primary endpoint up to 6 months after randomisation. Thereafter (>6 months), the incidence of the primary endpoint was lower in the telmisartan group than in the placebo group (13.6% vs. 15.2%). However, the interaction between treatment and time period was not statistically significant (p = ). The per-protocol set (PPS) included all patients of the full analysis set (FAS) who were taking study medication according to the trial protocol for the majority of their time in the study. The per-protocol analysis showed the consistency and confirmed the results obtained for the FAS; the hazard ratio of telmisartan vs. placebo for the primary endpoint was 0.95 (95% CI 0.82, 1.08). The incidences observed with the PPS were slightly lower than in the FAS, suggesting that

9 8 of 12 persistent use of study medication had a beneficial effect. A total of 30 subgroup analyses were performed for the primary endpoint, e.g. for core subgroups such as age, intrinsic factors, extrinsic factors, medical history, and concomitant medication use. No significant subgroup-by-treatment interactions were observed for the primary endpoint. Secondary and other endpoints The incidence of the secondary 3-fold composite endpoint of CV death, nonfatal MI, and non-fatal stroke, which was the primary endpoint in the HOPE study, was significantly lower in the telmisartan group (13.0%) than in the placebo group (14.8%). The hazard ratio for this comparison was 0.87 (95% CI 0.76, 1.00; p = ). For the 3-fold composite endpoint, the treatment difference was not consistent over time (time period-by-treatment interaction: p = ). No treatment difference was seen up to 6 months after randomisation. Thereafter (<6 months), the incidences of the 3-fold composite endpoint were significantly lower with telmisartan (11.3%) than with placebo (13.6%); the hazard ratio was 0.82 (95% CI 0.71, 0.95). The SBP-adjusted hazard ratio of telmisartan vs. placebo was 0.88 (95% CI 0.77, 1.01). The incidences of the 3-fold composite endpoint for the PPS were slightly lower than for the FAS; the hazard ratio of telmisartan vs. placebo based on the PPS was 0.89 (95% CI 0.77, 1.03). The incidence of all-cause mortality was 12.3% in the telmisartan group and 11.7% in the placebo group. The hazard ratio of telmisartan vs. placebo was 1.05 (95% CI 0.91, 1.22). The predominant reasons for death were CV death and malignancies. Telmisartan significantly reduced the risk of new microalbuminuria (HR 0.76), new macroalbuminuria (HR vs. placebo 0.66), of the composite of doubling of serum creatinine, progression to ESRD, new microalbuminuria, or new macroalbuminuria (HR 0.80), and had a beneficial treatment effect on the normalisation from micro- or macro- to normoalbuminuria (HR 1.39). The incidences for the doubling of serum creatinine were 2.1% in the telmisartan group and 1.3% in the placebo group; the hazard ratio of telmisartan vs. placebo of 1.58 was statistically significant. No treatment difference was observed for progression to ESRD. The incidence of newly diagnosed diabetes did not differ between treatment groups. The incidence of confirmed newly diagnosed diabetes (as assessed by

10 9 of 12 the investigators) was significantly lower with telmisartan than with placebo (HR 0.75, 95% CI 0.60, 0.95). In this trial, a higher rate of malignancies (overall and in patients without cancer at baseline) was observed in patients treated with telmisartan than in those treated with placebo. No differences between treatment groups were seen for fatal malignancies. So far, there is no evidence that ARBs are associated with a higher risk of malignancies. Chance findings due to multiple testing cannot be excluded. Safety results: The mean observation time during the run-in period was 25.2 days. During the randomised period, the overall mean observation time was about 4.6 years and comparable between treatment groups. While receiving the study medication (on treatment), the mean observation time was 1527 days in the telmisartan group and 1515 days in the placebo group. All differences between treatment groups described below for AEs were also observed after adjustment for observation time. Since the safety profile of telmisartan is well established, reporting of AEs was limited to AEs leading to permanent treatment discontinuation and SAEs. During the run-in period, study drug-related AEs leading to permanent treatment discontinuation were reported for 2.54% of patients. The most frequent AE leading to permanent treatment discontinuation was dizziness / vertigo / lightheadedness (0.68%). Serious adverse events leading to permanent treatment discontinuation during the run-in period were reported for only 7 patients (0.11%), with hypotension (n=3) being the most frequently reported. Non-fatal SAEs were reported for 1.83% of patients during the run-in period; these were mainly cardiac disorders. During the randomised period, 12.03% of patients died. Mortality overall and mortality while on treatment were slightly higher in the telmisartan group than in the placebo group (overall: 12.32% vs %; on treatment: 9.61% vs. 8.95%). However, when all-cause mortality was analysed as a secondary efficacy endpoint, no statistically significant difference between telmisartan and placebo was observed (HR 1.05; 95% CI 0.91, 1.22). The most frequently reported SAEs on treatment in association with death were sudden cardiac death (telmisartan: 2.34%; placebo: 2.25%) and myocardial infarction (telmisartan: 1.18%; placebo: 1.18%). The frequencies of primary causes of death and of SAEs reported in association with death while on treatment were generally comparable between treatment groups. The incidence of cardiac failure reported as SAE in association

11 10 of 12 with death was higher in the telmisartan group (0.91%) than in the placebo group (0.64%). The incidence of ventricular tachyarrhythmia was higher in the telmisartan group (0.20%) than in the placebo group (0.03%). Post-treatment, primary causes of death and SAEs in association with death were observed at comparable frequencies in both treatment groups. The frequencies of patients with non-fatal SAEs reported while on treatment were comparable between the 2 treatment groups (telmisartan: 57.24%; placebo: 58.51%). The frequencies of SAEs were also generally comparable between treatment groups on the system organ class and preferred term levels. However, SAEs belonging to the system organ class cardiac disorders were reported in fewer patients in the telmisartan group (24.51%) than in the placebo group (26.62%). The following preferred terms were reported in slightly fewer patients in the telmisartan group than in the placebo group: diabetes mellitus (6.60% vs. 8.04%), angina pectoris (14.15% vs %), and myocardial infarction (4.67% vs. 5.42%). In contrast, the preferred term intermittent claudication was slightly more frequently reported in the telmisartan group than in the placebo group (6.70% vs. 5.65%). The frequency of SAEs considered drug-related by investigators was low. Serious adverse events considered study drug-related by investigators were reported for 0.44% of patients in the telmisartan group and in 0.13% of patients in the placebo group. Adverse events leading to permanent treatment discontinuation were slightly more frequent in the telmisartan group (8.36%) than in the placebo group (7.57%). The most frequently reported AE leading to permanent treatment discontinuation was hypertension / higher blood pressure / uncontrolled high BP; it was less frequently reported in the telmisartan group (0.61%) than in the placebo group (1.01%). In contrast, hypotension / low BP (telmisartan: 0.71%; placebo: 0.37%) and dizziness / vertigo / lightheadedness (telmisartan: 0.74%; placebo: 0.30%) were more frequently reported in the telmisartan group than in the placebo group. As expected, further differences between the treatment groups were observed for other known side effects of telmisartan: Gastrointestinal symptoms, renal diseases, and increases in creatinine or potassium values were more frequently reported as AEs leading to permanent treatment discontinuation in the telmisartan group than in the placebo group. Discontinuations of trial medication because of non-fatal SAEs were rare (telmisartan: 0.34%; placebo: 0.24%). Cough, angioedema, hypotensive symptoms, syncope, diarrhoea, renal failure, and signs of renal dysfunction were defined post hoc as AEs of special interest.

12 11 of 12 The differences between treatment groups were analysed using the χ 2 -test. For this analysis, patients were considered if a respective SAE was documented, a respective reason for temporary or permanent treatment discontinuation was given, or, in the case of signs of renal dysfunction, if relevant clinical laboratory values were above a pre-specified limit. Overall, this analysis confirmed the established safety profile of telmisartan: For cough, angioedema, and renal failure, no relevant differences between telmisartan and placebo were observed, whereas hypotensive symptoms, syncope, diarrhoea, and signs of renal dysfunction were more frequent in the telmisartan group than in the placebo group. The difference seen for signs of renal dysfunction was mainly due to higher frequencies of patients with potassium values >5.5 mmol/l, with doubling of serum creatinine, and with temporary or permanent discontinuation of study medication due to renal dysfunction in the telmisartan group; the frequency of patients with need for dialysis was comparable between treatment groups. Mean increases in serum creatinine from baseline to the end of the study were higher in the telmisartan group (0.06 mg/dl) than in the placebo group (0.01 mg/dl). The proportions of patients with transitions from low or normal to high creatinine values (telmisartan: 16.6%; placebo: 11.6%) and with possibly clinically significant increases ( 1.5 mg/dl) in creatinine (telmisartan: 13.8%; placebo: 11.2%) were higher in the telmisartan group than in the placebo group. For serum potassium, a small mean increase from baseline was observed in the telmisartan group (0.05 mmol/l), whereas a small mean decrease was observed in the placebo group ( 0.07 mmol/l). The frequency of patients with transitions from low or normal to high potassium values was higher in the telmisartan group (3.6%) than in the placebo group (2.0%). Likewise, possibly clinically significant increases of serum potassium (>5.8 mmol/l) at any time were more frequent in the telmisartan group (1.8%) than in the placebo group (0.5%). For the remaining laboratory parameters investigated (total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglycerides, glucose), no relevant differences were observed between treatment groups. The analyses of AEs and clinical laboratory parameters in subgroups did not reveal unexpected differences from the overall study population. The frequencies of patients with markedly low BP (evaluated as sitting SBP <100 mmhg, sitting DBP <60 mmhg, or both sitting SBP <100 and DBP

13 12 of 12 <60 mmhg) were higher in the telmisartan group than in the placebo group throughout the randomised period. Between treatment groups, no relevant differences in ECG data were noted. Conclusions: The TRANSCEND study could not demonstrate that telmisartan was superior to placebo in reducing the 4-fold composite endpoint of CV death, non-fatal MI, non-fatal stroke, and hospitalisations for CHF in patients at high risk and intolerant to ACE-Is who received concomitant medication according to their medical needs and current medical guidelines. Telmisartan was shown to be superior to placebo in reducing the secondary 3-fold composite endpoint of CV death, non-fatal MI, and non-fatal stroke, which was the primary endpoint in the HOPE study. The treatment benefit of telmisartan observed for the 3-fold composite endpoint was due to lower incidences of the components 'non-fatal stroke' and 'non-fatal MI' in the telmisartan group. The treatment effect of telmisartan on the 3-fold composite endpoint was time-dependent, with a significant treatment benefit of telmisartan from 6 months after randomisation onwards. Overall, the established safety profile of telmisartan was confirmed also in patients at high risk of cardiovascular disease.

ADVANCE post trial ObservatioNal Study

ADVANCE post trial ObservatioNal Study Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute

More information

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular

More information

Predicting and changing the future for people with CKD

Predicting and changing the future for people with CKD Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University

More information

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing

More information

Chronic Benefit Application Form Cardiovascular Disease and Diabetes

Chronic Benefit Application Form Cardiovascular Disease and Diabetes Chronic Benefit Application Form Cardiovascular Disease and Diabetes 19 West Street, Houghton, South Africa, 2198 Postnet Suite 411, Private Bag X1, Melrose Arch, 2076 Tel: +27 (11) 715 3000 Fax: +27 (11)

More information

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT

More information

The EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada

The EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years

More information

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome

PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome CEDAC FINAL RECOMMENDATION PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that

More information

By Prof. Khaled El-Rabat

By Prof. Khaled El-Rabat What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Management of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA

Management of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA Management of New-Onset Proteinuria in the Ambulatory Care Setting Akinlolu Ojo, MD, PhD, MBA Urine dipstick results Negative Trace between 15 and 30 mg/dl 1+ between 30 and 100 mg/dl 2+ between 100 and

More information

Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care

Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process

More information

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain

More information

Microvascular Disease in Type 1 Diabetes

Microvascular Disease in Type 1 Diabetes Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course

More information

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients

More information

Metoprolol Succinate SelokenZOC

Metoprolol Succinate SelokenZOC Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic

More information

The CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES

The CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel

More information

Coral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.

Coral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure. Coral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.. Dr. Javier Ruiz Aburto, FACS, FICS Assistant Professor Ponce School of Medicine Puerto Rico

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

Clinical cases with Coversyl 10 mg

Clinical cases with Coversyl 10 mg Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive

More information

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD

More information

Efficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis

Efficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis Efficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis Dipak Kotecha, MD PhD on behalf of the Selection of slides presented at the European

More information

rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.

rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A

More information

TREATMENT AND COMPLICAtions

TREATMENT AND COMPLICAtions ORIGINAL CONTRIBUTION JAMA-EXPRESS Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic The Antihypertensive and

More information

Life After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention

Life After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention Life After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention No Relationships to Disclose The Need for Modern Renal Trials Increased rate of RAS diagnosis

More information

CANVAS Program Independent commentary

CANVAS Program Independent commentary CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received

More information

The ESC Registry on Chronic Ischemic Coronary Disease

The ESC Registry on Chronic Ischemic Coronary Disease EURObservational Research Programme The ESC Registry on Chronic Ischemic Coronary Disease Prof. Fausto J. Pinto, FESC, FACC, FASE, FSCAI Immediate Past-President, ESC University Hospital Sta Maria University

More information

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection

More information

DIABETES AND METABOLIC SYNDROME

DIABETES AND METABOLIC SYNDROME TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 48,508 20,091 41.4% 61.1 4.3 4/7 (57.1%) HR PROactive (Dormandy et al 61

More information

Case #1. Current Management Strategies in Chronic Kidney Disease. Serum creatinine cont. Pitfalls of Serum Cr

Case #1. Current Management Strategies in Chronic Kidney Disease. Serum creatinine cont. Pitfalls of Serum Cr Current Management Strategies in Chronic Kidney Disease Grace Lin, MD Assistant Professor of Medicine, University of California San Francisco Case #1 50 y.o. 70 kg man with long-standing hypertension is

More information

Hospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension

Hospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension (2003) 17, 665 670 & 2003 Nature Publishing Group All rights reserved 0950-9240/03 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Hospital and 1-year outcome after acute myocardial infarction in patients with

More information

Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?

Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular

More information

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.

More information

Cardiovascular Diseases and Diabetes

Cardiovascular Diseases and Diabetes Cardiovascular Diseases and Diabetes LEARNING OBJECTIVES Ø Identify the components of the cardiovascular system and the various types of cardiovascular disease Ø Discuss ways of promoting cardiovascular

More information

KDIGO conference on high CV risk associated with CKD. The role of BP in CKD stage 1-4

KDIGO conference on high CV risk associated with CKD. The role of BP in CKD stage 1-4 KDIGO conference on high CV risk associated with CKD The role of BP in CKD stage 1-4 Johannes Mann, MD & Catherine Clase, MB BChir Friedrich Alexander University, Erlangen-Nuremberg Munich General Hospitals,

More information

Quality Payment Program: Cardiology Specialty Measure Set

Quality Payment Program: Cardiology Specialty Measure Set Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

ASPIRIN AND VASCULAR DISEASE

ASPIRIN AND VASCULAR DISEASE ASPIRIN AND VASCULAR DISEASE SUMMARY Aspirin is an effective antiplatelet agent for patients with cardiovascular and cerebrovascular disease. Incidence of adverse effects and drug interactions increases

More information

ΥΠΕΡΤΑΣΗ ΚΑΙ ΣΤΕΦΑΝΙΑΙΑ ΝΟΣΟΣ Ι.Ε.ΚΑΝΟΝΙΔΗΣ

ΥΠΕΡΤΑΣΗ ΚΑΙ ΣΤΕΦΑΝΙΑΙΑ ΝΟΣΟΣ Ι.Ε.ΚΑΝΟΝΙΔΗΣ ΥΠΕΡΤΑΣΗ ΚΑΙ ΣΤΕΦΑΝΙΑΙΑ ΝΟΣΟΣ Ι.Ε.ΚΑΝΟΝΙΔΗΣ CAD: Statistics CAD is the largest killer of American males and females 13 million Americans have CAD 1.1 million MI s per year Every 26 seconds an American

More information

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in high-risk individuals: a randomised placebocontrolled

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in high-risk individuals: a randomised placebocontrolled Articles MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial Heart Protection Study Collaborative Group* Summary

More information

The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease

The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,

More information

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell

More information

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology

More information

ACCP Cardiology PRN Journal Club

ACCP Cardiology PRN Journal Club ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients

More information

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher,

More information

LOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING

LOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING LOW DOSE ASPIRIN FOR PROPHYLAXIS OF CARDIOVASCULAR DISEASE FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING Use of Low Dose Aspirin to Treat and Prevent Cardiovascular Disease In recent decades, aspirin

More information

ANTI- HYPERTENSIVE AGENTS

ANTI- HYPERTENSIVE AGENTS CLINICAL ANTI- HYPERTENSIVE AGENTS Jacqueline van Schoor, MPharm, BSc (Hons) Amayeza Info Centre Hypertension represents a major public health concern. It affects about a billion people worldwide and is

More information

Byvalson. (nebivolol, valsartan) New Product Slideshow

Byvalson. (nebivolol, valsartan) New Product Slideshow Byvalson (nebivolol, valsartan) New Product Slideshow Introduction Brand name: Byvalson Generic name: Nebivolol, valsartan Pharmacological class: Beta-blocker + angiotensin II receptor blocker (ARB) Strength

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 CARDENSIEL 1.25 mg, film-coated tablet B/30 (CIP code: 352 968-1) CARDENSIEL 2.5 mg, film-coated tablet

More information

Consensus Core Set: Cardiovascular Measures Version 1.0

Consensus Core Set: Cardiovascular Measures Version 1.0 Consensus Core Set: Cardiovascular s NQF 0330 Hospital 30-day, all-cause, riskstandardized readmission rate (RSRR) following heart failure hospitalization 0229 Hospital 30-day, all-cause, riskstandardized

More information

Update on Dronedarone and Cardiovascular Outcomes

Update on Dronedarone and Cardiovascular Outcomes Update on and Cardiovascular Outcomes Dr. Stuart Connolly MD McMaster University Hamilton Ontario Disclosure: Research grants, speaker fees and consulting honoraria from sanofi aventis has key structural

More information

EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events

EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events EVOLVE EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events N Engl J Med online Nov 3, 2012 Glenn M. Chertow, Geoffrey A. Block, Ricardo Correa-Rotter, Tilman B. Drüeke, Jürgen Floege, William

More information

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National Coronary Artery Disease

More information

Regulatory Experience in Reviewing CV Safety for Diabetes

Regulatory Experience in Reviewing CV Safety for Diabetes Regulatory Experience in Reviewing CV Safety for Diabetes Drugs Kristina Dunder MD, PhD, Alternate CHMP member MPA, Sweden Disclaimer The views and opinions expressed in the following PowerPoint slides

More information

New Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015

New Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 New Winners in the World of Heart Failure Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 Jessup 2014 Shaking Things Up 2003: FDA approved eplerenone for the treatment of heart failure

More information

SYNOPSIS. Clinical Study Report CN138002: Addendum 1. Individual Study Table Referring to the Dossier

SYNOPSIS. Clinical Study Report CN138002: Addendum 1. Individual Study Table Referring to the Dossier Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abilify Name of Active Ingredient: aripiprazole Individual Study Table Referring to the Dossier (For National Authority Use Only)

More information

Jared Moore, MD, FACP

Jared Moore, MD, FACP Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner

More information

Perioperative Medical Therapy: Beta Blockers, Statins, ACE-Inhibitors, ARB Effects on Mortality

Perioperative Medical Therapy: Beta Blockers, Statins, ACE-Inhibitors, ARB Effects on Mortality Perioperative Medical Therapy: Beta Blockers, Statins, ACE-Inhibitors, ARB Effects on Mortality Art Wallace, MD, PhD SF VAMC Chief of Anethesia and Vice Chair of Anesthesia and Perioperative Care UCSF

More information

Percutaneous Coronary Intervention versus Coronary Artery Bypass Graft in Acute Coronary Syndrome patients with Renal Dysfunction

Percutaneous Coronary Intervention versus Coronary Artery Bypass Graft in Acute Coronary Syndrome patients with Renal Dysfunction www.nature.com/scientificreports Received: 26 June 2017 Accepted: 22 January 2018 Published: xx xx xxxx OPEN Percutaneous Coronary Intervention versus Coronary Artery Bypass Graft in Acute Coronary Syndrome

More information

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi

More information

Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital

Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke

More information

CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016

CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016 CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016 WHAT IS AN EPISODE OF CARE? An episode of care is a grouping of a patient s health care claims for a unique

More information

Efficacy and Safety of Prescription Omega-3-Acid Esters (P-OM3) for the Prevention of Symptomatic Atrial Fibrillation

Efficacy and Safety of Prescription Omega-3-Acid Esters (P-OM3) for the Prevention of Symptomatic Atrial Fibrillation Efficacy and Safety of Prescription Omega-3-Acid Esters (P-OM3) for the Prevention of Symptomatic Atrial Fibrillation PR Kowey, JA Reiffel, KA Ellenbogen, GV Naccarelli, and CM Pratt for the OM-8 Clinical

More information

Drugs acting on the reninangiotensin-aldosterone

Drugs acting on the reninangiotensin-aldosterone Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School

More information

Contrast Induced Nephropathy

Contrast Induced Nephropathy Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)

More information

Blood Pressure Monitoring in Chronic Kidney Disease

Blood Pressure Monitoring in Chronic Kidney Disease Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American

More information

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients

More information

Aspirin for cardiovascular disease prevention

Aspirin for cardiovascular disease prevention POSITION STATEMENT Aspirin for cardiovascular disease prevention Joseph Hung, for the Medical Issues Committee of the National Heart Foundation of Australia RANDOMISED CONTROLLED TRIALS have proven that

More information

Local Coverage Determination (LCD) for Cardiac Catheterization (L29090)

Local Coverage Determination (LCD) for Cardiac Catheterization (L29090) Local Coverage Determination (LCD) for Cardiac Catheterization (L29090) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD

More information

ACC NY Cardiovascular Symposium

ACC NY Cardiovascular Symposium ACC NY Cardiovascular Symposium Peripheral Vascular Disease: Watch the Heart and the Brain Evolving Role of Exercise, ACE-Inhibitors, Interventional and Surgical Options Mark A. Creager, M.D President,

More information

Catheter-based mitral valve repair MitraClip System

Catheter-based mitral valve repair MitraClip System Percutaneous Mitral Valve Repair: Results of the EVEREST II Trial William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular

More information

For personal use. Only reproduce with permission from The Lancet publishing Group. Summary

For personal use. Only reproduce with permission from The Lancet publishing Group. Summary Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Christopher

More information

Hypertension Management Controversies in the Elderly Patient

Hypertension Management Controversies in the Elderly Patient Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No

More information

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets

More information

Clinical guideline Published: 23 July 2011 nice.org.uk/guidance/cg126

Clinical guideline Published: 23 July 2011 nice.org.uk/guidance/cg126 Stable angina: management Clinical guideline Published: 23 July 2011 nice.org.uk/guidance/cg126 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Individual Study Table Referring to Part of Dossier: Volume: Page:

Individual Study Table Referring to Part of Dossier: Volume: Page: 2.0 Synopsis Abbott Laboratories Name of Study Drug: ABT-639 Name of Active Ingredient: ABT-639 Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title

More information

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine New Clinical Trends in Geriatric Medicine April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine Objectives Review current guidelines for blood pressure (BP) control in older adults

More information

In-Ho Chae. Seoul National University College of Medicine

In-Ho Chae. Seoul National University College of Medicine The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering

More information

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were

More information

Technology appraisal guidance Published: 28 November 2012 nice.org.uk/guidance/ta267

Technology appraisal guidance Published: 28 November 2012 nice.org.uk/guidance/ta267 Ivabradine adine for treating chronic heart failure Technology appraisal guidance Published: 28 November 2012 nice.org.uk/guidance/ta267 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Mihai Gheorghiade MD

Mihai Gheorghiade MD Mihai Gheorghiade MD Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois On behalf of: Stephen J Greene MD; Javed Butler MD MPH MBA; Gerasimos Filippatos

More information

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines

More information

Talking about blood pressure

Talking about blood pressure Talking about blood pressure Mrs Khan 56 BP 158/99 BMI 32 Total cholesterol 5.4 (HDL 0.8) HbA1c 43 She has been promising to do more exercise and eat more healthily for the last 2 years but her weight

More information

Diabetes mellitus type 2 and angina pectoris : novel insights in diagnosis, prognosis and treatment Wiersma, J.J.

Diabetes mellitus type 2 and angina pectoris : novel insights in diagnosis, prognosis and treatment Wiersma, J.J. UvA-DARE (Digital Academic Repository) Diabetes mellitus type 2 and angina pectoris : novel insights in diagnosis, prognosis and treatment Wiersma, J.J. Link to publication Citation for published version

More information

The Road to Renin System Optimization: Renin Inhibitor

The Road to Renin System Optimization: Renin Inhibitor The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension

More information

Efficacy and Safety of Prescription Omega-3-Acid Esters (P-OM3) for the Prevention of Symptomatic Atrial Fibrillation

Efficacy and Safety of Prescription Omega-3-Acid Esters (P-OM3) for the Prevention of Symptomatic Atrial Fibrillation Efficacy and Safety of Prescription Omega-3-Acid Esters (P-OM3) for the Prevention of Symptomatic Atrial Fibrillation PR Kowey, JA Reiffel, KA Ellenbogen, GV Naccarelli, and CM Pratt for the OM-8 Clinical

More information

Clinical Trial Results Summary Study EN3409-BUP-305

Clinical Trial Results Summary Study EN3409-BUP-305 Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin

More information

Valsartan Amlodipine HCT Combination: Control To Goal. Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI. Prof of cardiology Ain Shams University

Valsartan Amlodipine HCT Combination: Control To Goal. Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI. Prof of cardiology Ain Shams University Valsartan Amlodipine HCT Combination: Control To Goal Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI Prof of cardiology Ain Shams University Sonesta Hotel Cairo Egypt December 4 th 5 th ; 213 Hypertension

More information

Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management

Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures

More information

CLINICAL QUALITY MEASURES Stage 1 Meaningful Use

CLINICAL QUALITY MEASURES Stage 1 Meaningful Use CLINICAL QUALITY MEASURES Stage 1 Meaningful Use * Eligible professionals (EPs) must report on 3 required core clinical quality measures (CQMs). If the denominator of 1 or more of the required core measures

More information

Linagliptin Renewed benefit assessment according to 35a Paragraph 5b Social Code Book V 1

Linagliptin Renewed benefit assessment according to 35a Paragraph 5b Social Code Book V 1 IQWiG Reports Commission No. A12-11 Linagliptin Renewed benefit assessment according to 35a Paragraph 5b Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment ( Linagliptin

More information

Randomized Design of ALLHAT BP Trial

Randomized Design of ALLHAT BP Trial Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* *Wright JT, Dunn JK, Cutler JA et al. JAMA 2005:293:1595-1608. 42,418 High-risk hypertensive

More information

Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine

Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline

More information

Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy. Ziad Hijazi, MD

Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy. Ziad Hijazi, MD Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy Ziad Hijazi, MD Uppsala Clinical Research Center (UCR) Uppsala University, Sweden Co-authors:

More information